標(biāo)題：Research Grade Milatuzumab 米拉組單抗,AntibodySystem Laboratories
鏈接：https://www.antibodysystem.com/product/213.html
名稱：Research Grade Milatuzumab米拉組單抗
別名：Milatuzumab米拉組單抗，CD74-DOX (ADC), MEDI-115, hLL1, hLL1-DOX (ADC)
CAS: 899796-83-9
貨號：DHC08001
適用物種：Human
寄主物種：Humanized
形式：Liquid
純度：>95%
克隆性：Monoclonal
同種型：IgG1-kappa
應(yīng)用：Research Grade Biosimilar
UniProt：P04233
靶點(diǎn)：HLA-DR antigens-associated invariant chain, HLA class II histocompatibility antigen gamma chain, CD74, CLIP, Ia antigen-associated invariant chain, DHLAG, Ii
用途范圍：僅用于科研
儲存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
產(chǎn)品購買聯(lián)系方式：027-65279366 /18162686757
郵箱：biolab-reagents@atagenix.com
QQ：2663991332
參考文獻(xiàn)：
Milatuzumab - a promising new immunotherapeutic agent. PMID: 19968579
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. PMID: 19053886
Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. PMID: 23427296
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. PMID: 19351768
Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. PMID: 20574049
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE). PMID: 33619162
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. PMID: 23209030
Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. PMID: 21228331
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. PMID: 25847298
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression. PMID: 22404985
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-kappaB dependent human transformed follicular lymphoma cell line. PMID: 24386925
Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab. PMID: 23025988
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? PMID: 22377620
FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. PMID: 22042694
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. PMID: 25754579
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach. PMID: 28466956
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. PMID: 24112026
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models. PMID: 37740214
Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates. PMID: 26927803
Emerging antibodies for the treatment of multiple myeloma. PMID: 27195659
Novel targeted therapies for mantle cell lymphoma. PMID: 22361516
CD74: a new candidate target for the immunotherapy of B-cell neoplasms. PMID: 17875789
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies. PMID: 24708159
The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival. PMID: 21417823
CD84 is a survival receptor for CLL cells. PMID: 23435417
CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. PMID: 22905972
Gateways to clinical trials. PMID: 19455266
Emerging immune targets for the treatment of multiple myeloma. PMID: 29421983
CD74 interferes with the expression of fas receptor on the surface of lymphoma cells. PMID: 25304249
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. PMID: 25937048
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. PMID: 19223402
The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. PMID: 36334452
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. PMID: 22271448
The European League Against Rheumatism (EULAR) - 17th Annual European Congress of Rheumatology (June 8-11, 2016 - London, UK). PMID: 27458612
